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Abstract 
As the treatment of Systemic Lupus Erythematosus (SLE) has become more effective 
the focus has partly shifted from main concern of short term morbidity and survival to 
long term complications such as osteoporosis. The aims of this thesis were to a) 
determine prevalence and risk factors of osteoporosis and of b) vertebral fractures c) 
evaluate if adequate osteoporotic treatment was provided d) determine if resistin, an 
adipokine with proposed pro-inflammatory properties, was associated with markers of 
inflammation or bone mineral density (BMD) and to e) investigate patients self 
reported health related quality of life (HRQOL) and its relationship to disease 
variables and employment status in female SLE patients. 
 
In this cross sectional study 163 female patients with SLE were examined during the 
winter and spring 2002-2003.  
  
BMD was significantly reduced in patients compared to expected calculated reference 
values. Bisphosphonates were taken by 35% of patients with osteoporosis and 36% of 
patients with osteoporosis and/or osteopenia and concomitant glucocorticosteroid 
medication. Factors associated with low BMD in SLE were markers of inflammation, 
impaired kidney function and disease damage in addition to the conventional risk 
factors, high age and low weight. Glucocorticosteroid, current and cumulative doses, 
were associated with BMD in simple but not in multiple regression models. 
Only 6 (4%) women had a history of a clinical vertebral fracture whereas 29% had 
radiological fractures. High age was the strongest risk factor of vertebral fracture. 
There were no significant differences regarding SLE specific variables or current or 
cumulative glucocorticosteroid doses between patients with or without vertebral 
fractures. 
 
The SLE patients scored their HRQOL significantly lower than age and sex matched 
references in all SF-36 subscales. Prevalent vertebral fractures did not have a major 
impact on HRQOL. In patients 64 years old or younger (n=142) 54% worked full or 
part time. Working ability was associated with low age and high scores (indicating 
better health) in physical SF-36 subscales.  
 
Serum levels of resistin did not differ between patients and controls. There were clear 
associations between high resistin levels and general inflammation, renal disease, 
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treatment with glucocorticosteroids and bone loss in the SLE patient group. Resistin 
was independently associated to inflammation in multiple logistic regression analyses. 
 
In conclusion, our results show that female patients with SLE have increased risk of 
low BMD and osteoporosis and few patients are treated adequately. Vertebral fractures 
are common but seldom diagnosed. More attention should also be given factors of 
importance to the patients HRQOL, which is scored considerably lower than in general 
population. We suggest that resistin has pro-inflammatory properties in SLE and 
possibly also influence bone quality negatively.   
  
Keywords: Systemic lupus erythematosus, bone mineral density, osteoporosis, 
vertebral fracture, health-related quality of life, SF-36, resistin, cross sectional study 
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Abbreviations 
BILAG British Isles Lupus Activity Group 
BMD  Bone mineral density 
BMP Bone morphogenetic proteins 
BMU bone remodelling unit 
CNS Central nervous system 
DKK-1 Dickkopf-1 
EBV Epstein Barr Virus 
ECLAM European Consensus Lupus Activity Measure 
ELISA Enzyme-linked immunosorbent assay 
HRQOL Health related quality of life 
HRT Hormone replacement therapy 
ICTP C-terminal telopeptide of type I collagen 
IFN Interferon 
Ig  Immunoglobulin 
IL Interleukin 
M-CSF Macrophage colony-stimulating factor 
OCP Osteoclast progenitor 
OPG Osteoprotegrin 
PICP C-terminal propeptide of type I procollagen 
PINP  N-terminal propeptide of type I procollagen  
PTH Parathyroid hormone 
QCT Quantitative computed tomography 
RA Rheumatoid arthritis 
RANK Receptor activator of NFκB 
RANKL Receptor activator of NFκB ligand 
RIA Radioimmunoassay 
SD Standard deviation 
SF-36 Medical Outcome Study Short Form-36 
SLAM Systemic Lupus Activity Measure 
SLE Systemic lupus erythematosus 
SLEDAI  Systemic Lupus Erythematosus Disease Activity Index 
SLEDAI-2K Systemic Lupus Erythematosus Disease Activity Index 2000 
SLICC/ACR  Systemic Lupus International Collaborative Clinics/ American Collage 
of Rheumatology damage index 
TGF Transforming growth factor  
Th T helper  
TNF Tumor necrosis factor  
WHO World Health Organisation 
Wnt Wingless 
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Systemic Lupus Erythematosus 
SLE is an intriguing disease often considered as a model-disease for autoimmunity. 
The common existence of auto-antibodies directed against double-stranded DNA, the 
keeper of our genetic information, most certainly contributes to the fascination of the 
disease. SLE flares give rise to several distinct and important disease manifestations. I 
will however address aspects primarily connected with long term disease, osteoporosis 
and vertebral fractures. I will also discuss factors, disease-related or demographic; 
those are associated to and may contribute to the evolvement of low BMD and 
vertebral fractures. Special interest is laid on resistin, an inflammation marker and pro-
inflammatory cytokine.  I will also focus on variables important to health related 
quality of life (HRQOL) in SLE.  
Clinical aspects and outcome 
SLE is a chronic autoimmune disease mainly affecting women. Female to male ratio 5-
10:1 
1
. The annual incidence in a Southern Swedish population is approximately 
4,5/100000 and the prevalence 68/100000 
2
. The SLE prevalence differs worldwide 
with the highest prevalence in black populations. This can reflect methodological 
differences but also be suggestive of the aetiology of the disease.  
The disease is characterized by production of a variety of auto-antibodies and multi-
organ systems involvement. Typical serological findings include anti-nuclear (ANA), 
anti-double stranded DNA (anti-DNA) and anti-Smith (anti-Sm) antibodies. These are 
also included in the disease criteria 
3
. Several different auto-antibodies have been 
shown to play a role in clinical manifestations. Especially high affinity anti-bodies are 
thought to be of clinical relevance 
4
. One tissue damaging mechanism in SLE is 
proposed to be caused by anti-DNA binding to DNA-containing debris in the blood 
stream. The DNA released from apoptotic cells in the form of nucleosomes form 
immune complexes together with anti-DNA. These settle in the glomerular basement 
membrane, activating the complement system which causes inflammation and tissue 
damage 
5, 6
. Another disease mechanism includes IgG auto-antibodies directed to cell 
surface antigens situated, for example, on red blood cells or thrombocytes. Fc 
receptors on macrophages bind to and will clear these opsonised cells by phagocytosis 
resulting in haemolytic anaemia or thrombocytopenia 
7, 8
.  Yet other antibodies, anti-
cardiolipin antibodies, affect the patient by interfering with the coagulation 
haemostasis increasing the risk of thrombosis and embolies 
9
.  
A Canadian survey of SLE manifestations at anytime during disease course showed 
following manifestations and frequencies; arthralgia (85%), skin rash including sun 
sensitivity and the typical malar or facial butterfly-rash (78%), constitutional 
symptoms (77%), renal involvement (74%), arthritis (63%),  Raynaud´s phenomenon 
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(60%), vasculitis (56%), central nervous system affection (54%), mucous membrane 
affection (52%),  lymphadenopathy (32%), pleuritis (30%), pericarditis (23%) 
10
.  
The disease course is varied. For some patients SLE flares are rare and mild, but an 
Italian study showed that 44% of the patients experienced at least one severe flare 
(defined as glomerulonephritis, major CNS or heart and lung manifestation, 
haemolytic or aplastic anaemia) during 15 years follow up 
11
. Survival rates have 
improved during the last 50 years reflecting not only earlier diagnose in milder cases, 
but also the possibility of more intensive immunosuppressive treatment when needed. 
More, but not enough, attention is given to long-term disease morbidity like renal 
failure, hypertension and cardiovascular disease.  Vigilance for infections and access 
to effective antibiotics is also important in SLE since the treatment, often including 
cytotoxic substances and glucocorticosteroids, increase the susceptibility to infections 
12
.  
Survival rates 5, 10 and 15 years from the diagnosis, presented in an Italian study, 
show 96%, 93% and 76% survival respectively
11
. Mortality was higher in patients 
suffering from inner organ affection than those with mild flares exclusively. A Danish 
retrospective study presented in 1999, showed a 4,6-fold increased mortality compared 
with general population 
13
. In a Swedish survey only mortality after 10 years disease 
duration exceeded that in an age and sex matched population. Atherosclerotic vascular 
disease, active disease manifestations and infections contributed to mortality 
2
. These 
causes of mortality were also confirmed in multinational studies of current causes of 
death in SLE 
14, 15
. 
Classification criteria 
Because of the varying SLE manifestations the diagnosis is based on criteria. The first 
set of criteria were defined in 1971 by the American Rheumatism Association and 
later revised in 1982 
3
. At least 4 of 11 criteria must be present, but not necessarily at 
the same time, table 1. The criteria were developed mainly for the purpose of clinical 
studies. The sensitivity and specificity for the criteria are 96% respectively. In clinical 
praxis SLE diagnosis is considered in a patient with auto-antibodies and autoimmune 
disease manifestations typical for SLE from at least two different organ systems, in the 
absence of a more plausible diagnosis.  
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Table 1. 
Criteria for classification of SLE. For identifying patients in clinical studies 4 or more 
of the 11 criteria must be present, serially or simultaneously. 
Criterion Definition 
1.  Malar rash Fixed erythema, flat or raised, over the malar 
eminences, tending to spare the nasolabial folds 
2.  Discoid rash Erythematosus raised patches with adherent keratotic 
scaling and follicular plugging; atrophic scaring may 
occur 
3.  Photosensitivity Skin rash as result of unusual reaction to sunlight by 
patient history or physician observation 
4.  Oral ulcers Oral or nasopharyngeal, usually painless, observed by 
physician 
5.  Arthritis Non-erosive arthritis involving two or more 
peripheral joints 
6.  Serositis Pleuritis OR pericarditis 
7.  Renal disorder Persistent proteinuria >0,5g/day or greater than 3+ if 
quantification not performed 
OR 
Cellular casts 
8.  Neurologic disorder Seizures OR psychosis, in the absence of offending 
drugs or known metabolic derangements 
9.  Hematologic disorder Haemolytic anaemia OR leukopenia (≥2 occasions) 
OR lymphopenia  (≥2 occasions) OR 
thrombocytopenia (in the absence of offending drugs) 
10.  Immunologic disorder  Anti-DNA (native DNA) OR anti-Sm OR anti-
phospholipid antibodies 
11.  Antinuclear antibody  
   Modifications were made in 1997 
16
 
 
Aetiology and Pathogenesis 
SLE is a multifactorial disease.  Genetic, hormonal and environmental factors are 
predisposing or contributing to disease development. There are racial differences with 
two to four-fold higher prevalence in non-Caucasian compared to Caucasian 
population 
1
. The concordance for SLE in monozygotic twins is 25% and about 2 % in 
dizygotic twins 
17
. Several gene-loci with probable linkage to SLE are known 
6
. Many 
of these genes share the property of coding for different components in the immune 
system.  Genes involved in antigen presentation, inhibition of lymphocyte activation, 
apoptosis and clearance of immune complexes are examples of genes where variants 
 12 
are associated with SLE 
18
. It is also known that deficiencies of factors early in the 
complement system frequently is associated with SLE 
19
 .  
Female sex-hormones, estrogens, are thought to contribute to the increasing incidence 
in SLE during female puberty and fertile ages 
20
 
21
.  It has been shown that estrogen-
containing contraceptives 
22
 and hormone replacement therapy (HRT) 
23
 slightly 
increase the risk of later developing SLE. Estrogens can also affect existing SLE. 
Contraceptives have not been found to increase the rate of severe flares in mild SLE 
24
. 
HRT has been reported to increase mild to moderate flares 
25
. However patients with 
phospholipid antibody syndrome and active renal disease were not included in the two 
latter studies. Estradiol affect the immune system in several ways 
26
 
27
. In murine SLE 
models, estradiol aggravates glomerulonephritis and can block the negative selection 
of naïve B-cells and thus enhance autoantibody production 
28, 29
.  
Several environmental factors have been mentioned as possible trigger factors of 
disease or SLE flares. Sunlight-exposure of sun-reactive skin is thought to trigger 
flares through events starting with DNA damage and increased apoptosis 
30
. Other 
environmental factors may influence individuals in favour of lupus, if specific genetic 
variants exist, or if applied at specific time points during life 
31
.  Factors with certain or 
possible influence before disease onset are frequent partake of alfalfa sprouts 
32
, 
smoking and getting blood transfusions 
33
, exposure to organic solvents, heavy metals, 
silica or  aromatic amines 
34
. Epstein Barr Virus (EBV) is one of several infections of 
possible importance to SLE development 
35
.  
Assessment of disease activity and disease damage in SLE 
SLE disease activity changes during time. To be able to measure and compare disease 
activity from time to time, for example when evaluating different medications or in 
clinical trials, different disease activity indices have been created. They transform 
disease manifestations and laboratory aberrations into numerals. There are several 
disease activity indices in routine clinical use. They have been validated and compared 
with each other 
36
. The British Isles Lupus Activity Group (BILAG) is an extensive 
index comprising eight organ domains. The organ manifestations are assessed as either 
non existent, new, worse or better 
37
. BILAG is often used in pharmaceutical testing. 
Another index is Systemic Lupus Activity Measure (SLAM) an index of medium 
length measuring changes in a broad spectrum of disease manifestations quantitatively 
over time 
38
 
39
. European Concensus Lupus Activity Measure (ECLAM ) 
40
 and 
Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) are other 
instruments for SLE activity. SLEDAI-2K  is a short instrument that measures 
ongoing, new or recurrent activity, as recognized by the clinician, during the last 10 
days 
41
, table 2. This is a minor modification of the original SLEDAI where only new 
or recurrent manifestations were registered. There is a high  correlation between the 
two versions of SLEDAI (r=0,97) 
42
. All manifestations should be caused by SLE and 
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each manifestation gives a score. SLEDAI-2K was used as disease activity 
measurement in the patient group presented in this thesis because it is widely used and 
easy to handle by both experts and trainees 
43
. It gives one index score per patient 
which is practical in further statistical analyses. The median (range) SLEDAI-2K value 
for the patients was 5(0-31) and mean value (SD) 6,7(6,0) (I-IV).  
The assessment of SLE prognosis requires, in addition to disease activity measures, an 
estimation of the organ damage caused by SLE. Systemic Lupus International 
Collaborative Clinics/ American Collage of Rheumatology damage index 
(SLICC/ACR), is the only widely used damage index 
44
, table 3. In this assessment 
specified irreversible damage in 12 organs or systems, occurring after the SLE 
diagnose and having  been present for at least 6 months, are recorded. SLICC/ACR is 
validated and reproducible between different observers 
44
 and therefore often used in 
clinical trials and clinical work. SLICC can however not distinguish between damage 
caused by SLE, its therapy or a concurrent disease but has shown to be associated with 
morbidity and mortality in several studies 
45
 
14
.   
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Table 2. SLEDAI-2K. Enter weight in SLEDAI score column if descriptor is present at the time of the 
visit or in the preceding 10 days. 
Weight SLEDAI 
SCORE 
Descriptor Definition 
8 □ Seizure Recent onset. Exclude metabolic, infectious or drug cause 
8 □ Psychosis Altered ability to function in normal activity due to severe disturbance 
in the perception of reality. Include hallucinations, incoherence, 
marked loose associations, impoverished thought content, marked 
illogical thinking, bizarre, disorganized, or catatonic behaviour. 
Excluded uremic and drug causes. 
8 □ Organic Brain 
Syndrome 
Altered mental function with impaired orientation, memory or other 
intelligent function, with rapid onset fluctuating clinical features. 
Include clouding of consciousness with reduced capacity to focus, and 
inability to sustain attention to environment, plus at least two of the 
following: 
perceptual disturbance, incoherent speech, insomnia or daytime 
drowsiness, or increased or decreased psychomotor activity. Exclude 
metabolic, infectious or drug causes. 
8 □ Visual Disturbance Retinal changes of SLE. Include cytoid bodies, retinal haemorrhages, 
serious exudates or haemorrhages in the choroids, or optic neuritis. 
Exclude hypertension, infection, or drug causes. 
8 □ Cranial Nerve 
Disorder 
New onset of sensory or motor neuropathy involving cranial nerves. 
8 □ Lupus Headache Severe persistent headache: may be migrainous, but must be 
nonresponsive to narcotic analgesia. 
8 □ CVA New onset of cerebrovascular accident(s). Exclude arteriosclerosis 
8 □ Vasculitis Ulceration, gangrene, tender finger nodules, periungual, infarction, 
splinter haemorrhages, or biopsy or angiogram proof of vasculitis 
4 □ Arthritis More than 2 joints with pain and signs of inflammation (i.e. tenderness, 
swelling, or effusion). 
4 □ Myositis Proximal muscle aching/weakness, associated with elevated creatine 
phosphokinase/adolase or electromyogram changes or a biopsy 
showing myositis. 
4 □ Urinary Casts Haeme-granular or red blood cell casts 
4 □ Hematuria >5 red blood cells/high power field. Exclude stone, infection or other 
cause. 
4 □ Proteinuria >0.5 g/24 hours.  
4 □ Pyuria >5 white blood cells/high power field. Exclude infection. 
2 □ Rash Inflammatory type rash. 
2 □ Alopecia Abnormal, patchy or diffuse loss of hair. 
2 □ Mucosal Ulcers Oral or nasal ulcerations 
2 □ Pleurisy Pleuritic chest pain with pleural rub or effusion, or pleural thickening. 
2 □ Pericarditis Pericardial pain with at least 1 of the following: rub, effusion, or 
electrocardiogram confirmation. 
2 □ Low Complement Decrease in CH50, C3, or C4 below the lower limit of normal for 
testing laboratory. 
2 □ Increased DNA 
binding 
Increased DNA binding by Farr assay above normal range for testing 
laboratory. 
1 □ Fever >38°C. Exclude infectious cause 
1 □ Thrombocytopenia <100,000 platelets/mm3, exclude drug cause. 
1 □ Leukopenia <3,000 White blood cell/mm3, exclude drug causes. 
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Table 3. SLICC/ACR. 
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Bone biology 
Bone structure and function 
The skeleton is vital for body posture, mobility and protection of inner organs. The 
maximum bone mass is reached at 25-30 years of age. There is a constant bone 
turnover and approximately 10% of the bone mass is exchanged every year. Bone 
resorption and formation exist simultaneously. The state of equilibrium can be 
dislocated for example in higher ages, by use of medication or bad nourishment, 
resulting in net loss of bone mass. There are two types of bone, the dense outer lining 
consisting of cortical bone and the porous, honeycombed appearing inner trabecular 
bone. Together they form a fairly light but hard and strong entity. The proportions of 
cortical and trabecular bone varies in different parts of the skeleton which affects the 
biomechanical characteristics and the turn over rate since trabecular bone is more 
metabolic active then cortical bone. Bone contains four cell types and an extra cellular 
matrix. The cells are osteoblasts, osteocytes, bone lining cells and osteoclasts. Ninety 
% of the organic bone matrix consists of collagen type I. Type I collagen can also be 
found in lower amounts in blood vessels, cornea, dentin, skin and tendon. In bone the 
type I collagen precursor is secreted by osteoblasts and forms a triple helix with 
extended carboxyterminal and aminoterminal ends. These are cleaved during secretion 
and a collagen fibril is formed. The collagen fibrils are subsequently mineralised by 
calcium-hydroxyapatit and other calcium salts. Type I collagen contribute to the 
elasticity of the bone which otherwise would be hard and brittle.  
Bone cells  
The osteoclasts resorb bone. Osteoclasts are derived from a hematopoetic cell linage, 
like macrophages, monocytes and dendritic cells. Under the influence of macrophage 
stimulating factor (M-CSF) and receptor activator of NFκB ligand (RANKL) the 
activated multi nuclear osteoclast is formed from a progenitor. Osteoblasts are 
responsible for bone formation and regulation of osteoclast differentiation. They are 
derived from mesenchymal stem cells which also are the progenitors of adipocytes, 
chondrocytes, myocytes and fibroblasts in the bone marrow stroma. Some of the 
factors of importance for osteoblast differentiation are bone morphogenetic proteins 
(BMP), transforming growth factor (TGFβ) and wingless (Wnt) proteins responsible 
also for aspects of osteoblast cell growth and function 
46
 
47
.  Mature osteoblasts restore 
bone by forming the osteoid. Osteoid contains bone matrix proteins like collagen type 
I and bone morphogenetic proteins (BMP). Osteoblasts also initiate the mineralisation 
or calcification of the osteoid by membrane bound alkaline phosphatase. In the process 
of mineralisation some osteoblasts are trapped in the new bone and become osteocytes. 
The osteocytes are sensitive to mechanical loading and initiate and signal need for 
bone remodelling in response to the loading and when micro-fractures occur 
48
. Bone-
lining cells are derived from osteoblasts and lie on mineralised bone surface 
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maintaining the microenvironment and possibly also initiating remodelling when 
needed. Figure 1. 
 
 
 
Figure 1. Schematic presentation of bone remodelling. 
 
1. Osteoclast 
resorbing bone 
Bone remodelling 
2. Osteoblasts 
forming osteoid 
3. Osteoblasts 
become osteocytes 
in mineralizing 
osteoid 
Osteoblast 
Bone lining cell 
Osteocyte 
Osteoid 
Osteoclast 
 18 
Bone remodelling and markers of bone turn over 
The bone remodelling cycle takes place at fixed sites called a bone remodelling unit 
(BMU) and begins with osteoclasts resorbing bone by releasing enzymes. Cathepsin 
K, acid phosphatases and metalloproteinases are released through the osteoclast´s 
lower, ruffled, boarder. The bone is demineralised and bone matrix proteins 
subsequently degraded giving rise to a resorption pit in the bone. In this process 
different degradation products like carboxyterminal telopeptide of type I collagen 
(ICTP) are released and can be measured in serum as a marker of bone resorption. 
Other degradation products as well as osteoclast enzymes can also be measured and 
used as bone resorption markers. When bone resorption is completed after 
approximately 10 days, bone formation and mineralisation follows. The whole 
remodelling process takes up to 3 months. During the bone formation phase, 
osteoblasts synthesise osteoid containing a precursor to collagen type I. The 
aminoterminal propeptide (PINP) and the carboxyterminal propeptide (PICP) are 
cleaved during maturation of collagen. These and other markers like bone-specific 
alkaline phosphatase and osteocalcin, can be measured in serum and reflect bone 
formation 
49-51
.  
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Osteoporosis  
Bone strength or structure is hard to measure in vivo, but bone mass can be measured 
by densitometry techniques. Osteoporosis is a systemic skeletal disease characterised 
by low bone mass and micro architectural deterioration of bone tissue resulting in 
increased risk for fractures.  
 
Normal and osteoporotic trabecular bone. 
Osteoporosis was defined according to World Health Organisation (WHO) as a bone 
mineral density (BMD) value at or below -2,5 SD, and osteopenia between -1 and -2,5 
SD, compared to the young adult mean value measured at any site using dual x-ray 
absorptiometry (DXA) 
52
. DXA is a method where x-rays of two different energy 
levels are used. The BMD is calculated after correction for other tissues. There are 
however some pitfalls. A skeleton with low calcification, not due to osteoporosis but 
to osteomalacia, will give a low BMD measurement and osteoarthritis or 
osteosynthetic material results in false high BMD. DXA measures bone as one entity 
while other methods like quantitative computed tomography (QCT) can distinguish 
between cortical and trabecular bone 
53
. The method in routine clinical use is however 
DXA. Low BMD does not cause any symptoms and the clinical implication of 
osteoporosis is the increased risk of skeleton fractures.  Osteoporosis can be primary; 
caused by aging, menopause and life style factors like smoking, alcohol, low physical 
activity, low sunlight exposure and insufficient intake of calcium or secondary; caused 
by diseases or medication, especially glucocorticosteroids 
54
. It is known that markers 
of inflammation in rheumatoid arthritis (RA) are associated to local joint bone loss and 
to generalised osteoporosis, indicating a common mechanism 
55
 
56
. Hence more 
inflammation and arthritis caused by withdrawal of glucocorticosteroids resulted in 
aggravated general loss of bone 
57
. 
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Bone and inflammation 
Differentiation of the osteoclast progenitor (OCP) and function and survival of the 
mature osteoclast requires M-CSF and RANKL that signals via the receptor activator 
of nuclear factor- κB (RANK) present on OCP and mature osteoclasts. RANKL can be 
expressed by almost all cell types but in bone and immune system by 
osteoblasts/stroma cells, fibroblast-like synoviocytes and activated T-cells and B-cells 
58
. RANKL is cell-surface bound but can be cleaved off 
59
. Interaction between 
osteoblasts and OCP are principally cell-cell interactions 
59, 60
. The action of RANKL 
can be inhibited by osteoprotegrin (OPG), a soluble decoy receptor that compete with 
RANK in binding to RANKL. OPG down regulate osteoclastogenesis and the 
activation of mature osteoclasts 
58
. OPG is produced by osteoblasts/ stroma cells in 
response to cytokines and anabolic agents like estradiol and BMPs 
61, 62
. OPG is down 
regulated by glucocorticosteroids, cyclosporine A and parathyroid hormone (PTH) and 
expression of OPG decline with age 
63-66
.  The ratio of RANKL/OPG determines and 
controls the osteoclast activity. All factors that affect the amount of RANKL or OPG 
will change the bone homeostasis. Proinflammatory cytokines, interleukine-1β (IL-
1β), IL-6, sIL-6R, TNF-α and others, stimulate osteoclast differentiation by mediation 
of the osteoblasts via up regulation of RANKL 
60, 67, 68
. In vitro studies have shown that 
regulatory T-cells have the capacity to inhibit osteoclast differentiation and function. 
This inhibition was dependent on cell-cell contact and was not mediated through the 
RANKL/OPG system 
69
.  
Osteoblasts mature in the stroma of the bone marrow. They migrate toward the bone 
surface where they secrete osteoid. Wnt proteins are a family of proteins synthesized 
by a group of “wingless” (Wnt) genes. Wnt signalling through the Wnt/β-catenin 
pathway increases osteoblastogenesis through stimulation of pre-osteoblast replication 
and inhibition of osteoblast and osteocyte apoptosis 
46
. Apocrine Wnt signalling in 
prostatic tumour cells have been shown to induce bone metastases 
70
.  Wnt signalling 
is modulated by the natural inhibitor Dickkopf-1 (DKK-1) 
71
. Glucocorticosteroids has 
been shown to induce DKK-1 expression in osteoblasts, thus inhibiting bone formation 
72
. Figure 2. 
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Figure 2. Schematic representation of bone cell development and the influence of 
inflammation. 
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Osteoporosis in SLE 
Some risk factors of osteoporosis are of special interest in SLE. SLE affects 
predominantly women and women have increased risk of osteoporosis compared to 
men. It has been shown that women with SLE have an earlier menopause than women 
in general 
73
. Sun avoidance is recommended in SLE and is associated with risk of  
deficiency in vitamin D necessary for bone formation 
74
. Possibly physical activity in 
SLE patients is lower because of arthralgias and constitutional symptoms. It has 
recently been shown that aerobic capacity is impaired in women with SLE regardless 
of disease activity or disease damage 
75
. Glucocorticosteroids, known to induce 
osteoporosis, is frequently used in SLE. Regardless of geographic origin of studies, 
prevalence of current usage of glucocorticosteroids often exceeds 50% and ever taking 
them differs between 60-98% in cross sectional studies. Other medications with 
possible side effects on BMD are cytotoxic substances and immunosuppressants used 
in treatment of SLE flares. Specific trials are rare but one study found BMD to be 
uninfluenced by intravenous cyclophosphamide during follow up time of 2 years 
76
. 
However cyclophosphamide can induce menopause 
73
 which enhance BMD loss.  
Several studies have demonstrated that low BMD and osteoporosis is more common in 
SLE than in general population 
77-80
 
81
 (I) .  It has also been shown that already 
premenopausal patients have reduced BMD 
77
 but this was barely found in a Chinese 
study with low prevalence of osteoporosis 
82
.  There is no controversy that general risk 
factors like high age and being postmenopausal also apply for SLE patients. There are 
however different findings regarding the role of glucocorticosteroids and SLE 
inflammation with respect to influence on bone. Which of these factors that have the 
largest impact on BMD is an intricate question since glucocorticosteroids is generally 
used as medication against SLE inflammation. Several studies have shown lower 
BMD in SLE patients using glucocorticosteroids 
80, 83-85
 and that premenopausal 
women are especially affected 
80
. The cumulative dose of glucocorticosteroids is 
associated to decreased BMD 
86
. There might be a threshold mean daily doses of at 
least 7,5 mg prednisolone taken during 2-3 years to affect BMD 
84
 
87
, or ever taking 
doses of at least 10 mg 
88
. Other studies find a weak association between BMD and 
glucocorticosteroids 
76
 or no association to current dose 
78, 79, 81, 89
 (I) or cumulative 
dose
77, 78, 81, 89, 90
 (I).  In one study BMD was not lower in 38 patients on long term 
glucocorticosteroid therapy than in controls, but there was an increase in biochemical 
markers of bone turnover 
91
, table 4. Influence on BMD by disease damage is also 
shown in several studies 
81, 85, 90, 92
 (I) and association to disease activity have been 
shown in some cross sectional studies. However disease activity should be prolonged 
to be able to give measurable lower BMD and is therefore best studied in longitudinal 
studies. Disease duration is frequently associated to BMD. In all patients disease 
duration naturally increases by age. Long disease duration could even include patients 
passing from pre- to post-menopause. Therefore it is especially interesting that 
 23 
osteoporosis in juvenile SLE patients also is associated with longer disease duration 
93
, 
figure 3. 
 
Figure 3. Risk factors of osteoporosis. Roman numerals refer to the papers in this 
thesis. 
There are factors, apart from the usual treatments of osteoporosis, which are associated 
with maintenance of BMD in SLE. Regular exercise was protective of femoral neck 
BMD loss 
81, 84
 (I) and usage of hydroxychloroquine preserved BMD in hip 
85
 and 
spine 
85, 94
.  Taken together there are indications that ordinary osteoporotic risk factors, 
glucocorticosteroids and inflammation interact and contribute to osteoporosis in SLE 
patients. Glucocorticosteroids may diminish negative effects on bone caused by SLE 
inflammation if used in correct doses and in the right patients. 
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Age 
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Low vitamin D 
Female sex 
Weight/BMI 
Height 
Early menopause 
Family history of fracture 
Physical inactivity 
Smoking 
Glucocorticosteroids 
 
 
SLE-specific risk factors 
 
Cytotoxic medication (I) 
Disease damage/ Kidney 
function (I) 
Inflammation (I) 
Resistin (IV) 
 
 
OSTEOPOROSIS 
 24 
Table 4. BMD in SLE and glucococorticosteroids as a risk factor for low BMD. 
Reference Study design Patient number Female 
% 
Age 
mean±SD, if not 
indicated otherwise 
Glucocorticosteroids risk 
factor for low BMD 
Yes (+), No (-) 
BMD  
SLE vs. controls 
Kalla 
79
 (1993) Cross sectional 46 SLE 
108 controls 
100% 31±7 
32±8 
- 
 
 
SLE < controls 
Formiga 
77
 (1995) Cross sectional 74 SLE 
50 controls 
100% 30,8±6,5  
30,8±6,9 
- 
 
 
SLE < controls 
Kipen 
95
 (1997) 
 
Cross sectional 
 
97 100% 44,2±14,9 
 
+  
Hansen 
76
 (1998) Longitudinal 2 years 
 
36 86% Median (range) 39 (28-53) (+)  
Li 
82
 (1998) Cross sectional 52 SLE 
52 controls 
100% 34,1±8,0 
33,7±7,7 
 
(+)  
Kipen 
84
 (1999) Longitudinal 3 years 
 
32 100% Mean (SEM) 35,2 (1,5) Lumbar spine loss if 
prednisolone ≥ 7,5mg  
 
 
Sinigaglia 
83
 (1999) 
 
Cross sectional 
 
84 
 
100% 30,5±7,5 +  
Gilboe 
80
 (2000) Cross sectional 75 SLE 
75 RA 
75 controls 
88% Median (range) 45 (20-70) 
Median (range) 45 (22-70) 
Median (range) 45 (20-70) 
 
+ SLE < controls 
SLE and RA similar  
Jardinet 
87
 (2000) Longitudinal  
2 years 
 
35 100% 30±9 Lumbar bone loss if 
prednisolone > 7,5 mg 
 
Becker 
92
 (2001) Consecutively 64 52% Female: 33±9,2 
Male: 36±11,1 
 
+  
Lakshaminarayanan 
85
 
(2001) 
Consecutively 92 
 
100% 45,9±12,4 +  
       
Coimbra 
78
 (2003) Cross sectional 
 
60 SLE 
64 controls 
 
100% 32,8±8,6 
31,1±7,2 
- SLE < controls 
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Korczowska 
91
 (2003) Cross sectional 
 
38 SLE  
160 controls 
100%  - 
 
SLE = controls 
       
Uaratanawong 
86
 (2003) Cross sectional 118  
 
100% Corticosteroids 31,8±8,1 
No Corticosteroids 34,0±7,9 
 
+  
Bultink 
89
 (2005)                    Consecutively 
 
107 93% 41±13 -  
Mok 
94
 (2005) 
 
Cross sectional 34 100% 52,9±4,9 Not evaluable.  
 
 
Yee 
88
 (2005) 
 
Cross sectional 
 
242 95,5% Median (range) 40 (18-80) Prednisolone > 10 mg/day  
Lee 
90
 (2006) 
 
Cross sectional 
 
307 100% 41,7±11,1 -  
Almehed 
81
(I) (2007) Cross sectional 163 100% Median (range) 47 (20-82) - SLE< calculated 
control value  
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Vertebral fractures  
The mean 10-year probability of getting a vertebral fracture in general female Swedish 
population has been estimated to 7,2% at 50 years of age, increasing to 26,7% at 85 
years of age 
96
. An existing, prevalent, vertebral fracture is a risk factor of new 
fractures and of mortality 
97
 
98
. There is a small risk of getting vertebral fractures in 
spite of normal BMD 
96
 although low energy fractures like vertebral are typical 
osteoporotic fractures. Vertebral compression fractures can occur almost 
spontaneously in a fragile skeleton. Since fracture symptoms can be hard to distinguish 
from other causes of back pain, prevalence of vertebral fracture will differ depending 
on if radiographic or clinical fractures are assessed. The vertebra consists mainly of 
trabecular bone which is surrounded by a thin cortical layer. Events influencing 
trabecular strength or spinal mechanical loading will facilitate vertebral compressions. 
There are different methods of analysing conventional radiographs for fractures. These 
include semiquantitative and quantitative morphometric methods which have been 
found equivalent if performed by skilled radiologists 
99
. Figure 4. 
Higher prevalence of vertebral fractures have been found in female SLE patients than 
in age matched controls 
100-102
 and already in premenopausal ages 
100
. A high 
proportion of women suffered from vertebral fractures in spite of normal BMD 
103
 (II). 
Risk factors of fracture in SLE were high age, postmenopausality or disease duration 
88, 89, 102, 103
 (II), low BMD 
88, 89, 100
, vitamin D deficiency 
89
 and  glucocorticosteroid 
medication 
89, 102
.  In some studies associations between fractures and 
glucocorticosteroids were analysed but not found 
88, 100, 103
(II). Table 5.  
Comparisons of female post-menopausal patients on chronic glucocorticosteroid 
therapy but with different diseases reveal differences in prevalence of vertebral 
fractures 
104
. SLE patients had fewer fractures than patients with several other 
inflammatory diseases. It is also known that fracture risk is higher with 
glucocorticosteroid treatment than without at a given BMD 
105
. Taken together, the 
impact of glucocorticosteroids on vertebral fractures in SLE is still uncertain. Estrogen 
deficiency has known effects on bone metabolism resulting in net bone loss and lower 
BMD. Estrogen deficiency in general female population has also been proposed to 
effect connective tissue and intervertebral disc components leading to reduced disc 
height and loss of shock-absorbing properties 
106
. Female SLE patients have earlier 
menopauses than healthy women which could have some relevance when comparing 
fracture prevalences 
73
. Vitamin D deficiency increases serum PTH which leads to 
increased bone resorption and osteoporosis. Severe Vitamin D deficiency causes 
osteomalacia where new bone matrix, osteoid, is not mineralized resulting in soft bone 
and sometimes fractures 
74
. Several risk factors for fractures apply specially to SLE 
patients and should be recognised. These factors mainly agree with the risk factors for 
osteoporosis, figure 3, but include factors increasing the risk of falling like sight 
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reduction and alcohol use. Vertebral fractures seldom come to clinical attention (II) 
and therefore spine radiograph should be liberally considered in SLE patients. 
Non-vertebral fractures and SLE 
Self-reported fractures (vertebral and non-vertebral) were five times more common in 
SLE patients compared to general population in a large population-based American 
study. High age and long term treatment with glucocorticosteroids were associated 
with fracture 
102
. In cross sectional studies longer duration of SLE 
103
 and low BMD 
was associated with fractures 
88, 103
. 
Figure 4. Semiquantitative visual grading of vertebral deformities 
107
. Graphic representation. 
 
Table 5. Fractures and risk factors of fracture in SLE.  
Reference Study design Patient number Female 
% 
Age 
mean ± SD, if not 
indicated otherwise 
Vertebral fractur (V) 
Peripheral fracture (PF) 
Clinical fracture (CF)  
Radiological fracture 
(RF) 
Percentage of fractures,  
SLE vs. control  
Glucocorticosteroids risk 
factor for fracture:  
Yes (+), No (-) 
Low BMD risk factor for 
fracture: Yes (+), No (-) 
Ramsey-Goldman 
102
 
(1999) 
Retrospective 
cohort 
702 SLE 
US population 
controls (NHIS) 
 
100% 45,4± 13,1 V, PF, CF SLE > control Glucocorticosteroids : + 
Low BMD: Not assessed 
Yee 
88
 
(2005) 
Cross sectional 242 95,5% Median (range) 
39,9 (18-80) 
V, PF, CF  Glucocorticosteroids : -  
Low BMD: + 
 
Borba 
100
 
(2005) 
Cross sectional 70 SLE 
20 controls 
100% 31,8±8,1 
32±8,9 
V, RF SLE > controls Glucocorticosteroids : -  
Low BMD: - 
 
Bultink 
89
 
(2005) 
Consecutively 107 93% 41± 13 V, RF  Glucocorticosteroids : +  
Low BMD: - 
        
Lee 
103
 
(2007) 
Cross sectional 307 100% 41,7± 11,1 CF  Glucocorticosteroids : -  
Low BMD: - 
 
Rhew 
101
 
(2008) 
Longitudinal 
2 years 
100 SLE 
100 controls 
100% 44,1± 11,1 
44,5± 10,7 
V, PF, CF SLE > controls 
(incident nonvertebral 
fractures) 
Glucocorticosteroids : -  
Low BMD: - 
        
Almehed (II) Cross sectional 163 100% Median (range)  
47 (20-82) 
V, RF  Glucocorticosteroids : -  
Low BMD: - 
NHIS: National Health Interview Survey
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Health related quality of life in SLE 
SF-36 
Health was defined by WHO as "a state of complete physical, mental and social well
 
being and not merely the absence of disease or infirmity" 
108
. Health is a subjective 
judgement of greatest importance to the patient but without obvious disease correlates. 
There are several assessments for different aspects of health and quality of life. Some, 
like the Health Assessment Questionnaire (HAQ), are developed as disease specific 
assessments while others, for example Medical Outcome Study Short Form-36 (SF-
36), is a generic instrument of physical and mental components of self-reported health 
related quality of life (HRQOL) 
109-111
. The concepts of SF-36 are not specific to any 
age or disease which for example allows comparisons between patient groups with 
different diseases. This property and the possibility of digital processing have made 
SF-36 widely used.  SF-36 is a validated 36 item questionnaire comprising 8 domains 
of physical and mental health. The physical domain consists of physical functioning 
(PF), role limitations due to physical problems (RP), bodily pain (BP), general health 
(GH) and the mental domains consist of vitality or energy level (VT), social 
functioning (SF), role limitations due to emotional problems (RE) and mental health 
(MH). The questions refer to the previous month.  SF-36 has been validated in a 
Swedish version 
110
and in SLE 
112
.  
Factors with impact on HRQOL in SLE 
HRQOL is scored worse, multidimensional, by SLE patients compared to matched 
controls 
113-115
 (III). SLE patients score HRQOL better (higher) than RA patients, 
especially with regard to physical function 
114, 115
. In one study which used the Quality 
of life scale (QOLS-S) there was no difference between SLE and RA patients, but RA 
patients scored worse in pain score than SLE patients using Arthritis Impact 
Measurement Scales (AIMS) 
116
. In comparison to patients with other chronic illnesses 
like congestive heart failure or former myocardial infarction, SLE affect all health 
domains in SF-36 more, and at earlier ages 
117
. However when compared to patients 
with fibromyalgia, SLE patients score higher (better) in several dimensions of 
HRQOL. Fibromyalgia is one contributor to worse HRQOL in SLE 
118, 119
 as is 
depression and anxiety 
120
. Fatigue and the unpredictable course of the disease, the loss 
of control over the body, were areas  especially mentioned by SLE patients as 
influencing the quality of life in a Swedish study
121
. SLE disease activity and damage 
scores are often regarded as poor indicators of HRQOL since results regarding 
associations to SF-36 are not uniform 
122
 (III). However health status measures 
correlated better to disease damage index  than disease activity indicating that some 
health measures can capture the consequences of disease over time 
114
. In female 
postmenopausal population with osteoporosis (but without SLE), vertebral fractures 
contributed significantly to low HRQOL, especially if the fracture was located in 
lumbar spine 
123, 124
. In SLE, prevalent vertebral fractures were only associated with PF 
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which was significantly lower than in patients without fracture (III). However few 
patients had fractures in lumbar spine.  
HRQOL and work in SLE 
Employment rates in SLE are not only related to disease specific factors but also to 
basic socioeconomic conditions, general employment rates and the present disability 
pension system. Several factors apart from SLE also influence patients HRQOL. This 
must be remembered when interpreting study data. In a small Swedish unselected SLE 
population two years disease did not influence employment rates from that in normal 
population 
125
, but absence due to sickness was common. In an American study with 
900 working SLE patients included, the proportion of employed patients after 5 years 
disease was approximately 85% and after 10 years 60% 
126
. In a Dutch study with 59% 
unemployment rate reduced HRQOL, higher age at disease onset, neuropsychiatric 
organ damage and diabetes were associated with unemployment in SLE. In an 
American study with 43% work-disability among SLE patients disease damage, pain 
and fatigue was associated with work-disability 
127
. In a Swedish study with 42% 
unemployment, 40% work disability, patients working scored higher in all SF-36 
subscales than patients with work-disability. Low age and high PF and RP were 
associated with the capacity to work (III).  
Factors improving HRQOL in SLE  
Several factors are known to be associated with HRQOL but few studies have looked 
at the possibility of specific intervention to improve HRQOL in SLE.  Improved 
physical health has however been associated with better coping strategies and 
improved mental health. Improved mental health has been associated with better 
family support, lower disease activity and glucocorticosteroid dose, non-use of 
cytotoxic drugs and better physical health 
128
. Thus a potentially modifiable factor in 
SLE treatment, apart from optimized medical treatment of the disease itself, is 
education of the patients and their families aiming at better coping strategies and 
support.  
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Inflammatory markers in SLE 
Since SLE includes diverse disease manifestations of different severity, there is need 
to identify specific biomarkers of SLE activity. Up today disease activity measure is 
mainly performed with assessments like SLEDAI, BILAG or SLAM. There is ongoing 
search for more specific markers of disease activity, inflammation, and prediction of 
SLE flares. In the T helper cell (Th) Th1/Th2 model, cytokines produced by CD4+ T 
helper cells are functionally grouped in Th1 and Th2 cytokines. Th1 cytokines mainly 
induces cellular immunity; IL-2, IL-12, interferon (IFN)-γ and Th2 cytokines mainly 
induces humoral immunity and antibody production; IL-4, IL-5, IL-6 and IL10 
129, 130
. 
An uneven balance in Th cytokine production could favour the development of certain 
diseases in susceptible individuals. Dominance of Th 2 cytokines has been shown in 
SLE 
131
 although results are not totally consistent 
132
.  Measurement of interleukins 
have however not so far been of great clinical value, with the exception of 
measurement in cerebrospinal fluid in CNS lupus 
133
. Complement factors, especially 
factors early in the classical activation pathway, are of clinical interest in lupus 
134
. 
Antibodies against C1q are found in autoimmune diseases like SLE, sometimes in 
infections, and are linked to immune-complex disorders. The physiological role of C1q 
is clearance of immune complexes and apoptotic cells from the organism. In SLE C1q 
deficiency is associated with nephritis 
135, 136
.  Decrease in C3 and C4 have also been 
described prior to and in SLE flares, mainly in kidney and haematological affection 
137
 
138
. Together with decreasing complement levels rising concentrations of anti-dsDNA 
in serum has been shown to predict major exacerbations 
138, 139
. 
Resistin 
Resistin is a low molecular weight, cystein rich secretory peptide discovered some 
years ago by three different groups 
140-142
. In rodents resistin is mainly produced in 
white adipose tissue and may be the linkage between obesity and insulin resistance. 
There is however only a 59% homology at protein level between resistin in  mouse and 
in humans, and the genes are coded on different chromosomes 
143
. In man resistin is 
expressed mainly in macrophages and other myeloic cells 
144
 but also in osteoblasts 
and osteoclasts 
145
 and several other tissues 
146
. In general population resistin is higher 
in females than in males and associated with elevated CRP or IL-6 
147, 148
. Resistin 
levels are higher in patients with impaired renal function 
149-151
  but this relation is not 
present in normal or mildly impaired function 
152
. Resistin has been associated with 
vascular inflammatory markers in type 2 diabetes mellitus 
153
, with prolonged 
inflammation during sepsis 
154
, with inflammation in obstructive sleep apnea 
155
,  
Crohn´s disease 
156
,  RA 
157-159
, local salivary gland lymphocytic inflammation in 
Sjögren´s Syndrome 
160
 and with inflammation and glucocorticosteroid medication in 
SLE (IV).  
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In vitro studies on peripheral blood mononuclear cells show that resistin increase 
mRNA expression of IL1, IL-6 and TNFα 159. In addition, resistin expression is up 
regulated by the same cytokines 
161
. Resistin has been shown to stimulate 
osteoclastogenesis in vitro via NFκB pathway, possibly via osteoblast IL-6 secretion 
145
 indicating a role for resistin in bone remodelling. In general male population no 
clear-cut association between resistin and BMD has been demonstrated 
162, 163
. In RA 
association was found between resistin and low BMD 
158
 and this was also shown in 
SLE (IV).  Resistin could be a key cytokine in SLE inflammation. There is need for 
disease mechanisms explaining both general inflammation and long term disease 
complications like osteoporosis and cardiovascular disease. The role of resistin in 
humans with regard to insulin resistance and possibly vascular disease is not as clear 
as in rodents. However data indicate interplay between inflammation, resistin and 
endothelial dysfunction 
164-166
. This would make resistin a perfect target for medical 
intervention in SLE, influencing both inflammation and cardiovascular complications. 
We therefore look forward to further studies regarding resistin and possible 
mechanisms of action in general and in SLE.  
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Patients and methods 
Patients 
Three hundred thirty-nine patients, men and women, with SLE were identified from 
the patient administrative registers in the rheumatology clinics in Göteborg and Borås. 
The patients were invited to participate in a cross sectional study investigating; Paper 
I. Frequency and determinants of osteoporosis in SLE. Paper II. Frequency and 
determinants of vertebral fractures in SLE. Paper III. Health related quality of life in 
SLE. Paper IV. Possible important markers of osteoporosis and/or inflammation in 
SLE. 
All patients  completing the study were at least 18 years old and fulfilled at least four 
of the 1982 American Collage of Rheumatology (ACR) classification criteria for SLE 
3
. Exclusion criteria were pregnancy and not speaking Swedish.  
One hundred eighty-two patients, 163 women and 19 men, completed the survey. The 
procedure of enrolment to the study and reasons for discontinuation are shown in 
figure 5.  Only results from female participants are analyzed. In Paper I, II and IV 
results from 163 female SLE patients are shown. In Paper III 150 female patients are 
analyzed. Thirteen of the patients were excluded in this analysis because of lacking 
radiographs of thoracic and lumbar spine, one examination was not performed and 
twelve analogue radiographic pictures were damaged by a flooding of the archive.  
All patients gave informed written consent prior to participation and the study was 
approved of by the Ethics Committee at Sahlgrenska Academy at University of 
Gothenburg. 
Controls 
Paper I.  A  control BMD was calculated for each patient using the equations for Z-
score estimations from the Lunar Prodigy (12165) software, provided by GE 
Healthcare. These adjust the BMD values for age and weight 
167
. 
Paper III. An age and sex-matched reference group (n=1045) was randomly selected 
from the Swedish SF-36 national normative database (n=8930). 
Paper IV. The control group consisted of 12 female healthy blood donors and 30 
healthy female staff members and PhD students in the department of Rheumatology. 
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Figure 5. Procedure of enrolment to study and reasons for discontinuation. 
  
Questionnaire 
Paper I-IV.  All patients answered self administered questionnaires about age, duration 
of disease, medication, intake of cheese and milk, smoking habits, physical activity, 
menopausal status, fractures obtained after 25 years of age and current mean of 
livelihood. DMARD medication was recorded as either a single treatment or 
combinations of two or three DMARDs. Dietary calcium intake was calculated from 
information on average intake of cheese and milk.  
339 patients identified and asked for 
participation 
(298 women, 41 men) 
 
234 patients replied 
(210 women, 24 men) 
(Reply frequency: women 70%, men 
59%, over all 69%) 
 
204 patients enrolled 
(184 women, 20 men) 
 
 
182 completed study 
(163 women, 19 men) 
30 patients were not able to 
participate 
(26 women, 4 men) 
18 patients did not meet inclusion 
criteria  
(18 women) 
 
4 patients did not complete study 
(3 women, 1 man) 
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Cumulative corticosteroid intake was calculated as thoroughly as possible by reading 
all patients medical records. 
Assessment of disease activity, disease damage and quality of life 
Paper I-IV. Disease activity was scored by the Systemic Lupus Erythematosus Disease 
Activity Index (SLEDAI-2K) 
41
 and disease damage was recorded according to 
Systemic Lupus International Collaborative Clinics (SLICC/ACR) 
44
. Health related 
quality of life was assessed by the Swedish version of the Medical Outcome Study 
Short Form-36 (SF-36) 
168
 , also validated in patients with SLE 
112
. SF-36 was the 
questionnaire first answered by each patient. 
Laboratory methods 
Paper I-IV. Venous blood samples were obtained in the morning after an overnight fast 
and serum was stored at -70°C until analysis. ESR, CRP, creatinine, blood cell count, 
ionized calcium, total cholesterol, HDL, LDL, triglycerides and complement factor C3 
and C4 were measured consecutively using standard laboratory techniques. Urinary 
samples were also analysed consecutively. 
Quantitative sandwich ELISA kits were used for measurement of proinflammatory 
cytokines TNFα, IL1β, IL6 and sIL6R (Quantikine, R& D Systems, Minneapolis, 
USA).  
The bone resorption marker, C-terminal telopeptide of type I collagen (ICTP), and the 
bone formation marker, N-terminal propeptide of type I procollagen (PINP), were 
analysed quantitatively in serum by radioimmunoassay (RIA) (Orion Diagnostica, 
Espoo, Finland). Resistin levels were detected with a sandwich ELISA (R & D 
Systems, Minneapolis, USA). The detection limit of the assays were: TNFα 0,12 pg/ml 
, IL1β 0,1 pg/ml, IL6 0,7 pg/ml  and sIL6R 6,5 pg/ml, ICTP 0,7 μg/l, PINP 2 μg/l and 
resistin 31 pg/ml. 
Bone mineral density 
Paper I-IV. BMD was measured at the lumbar spine (L2-L4), non dominant hip 
(femoral neck and total hip) and non dominant distal forearm (the diaphysal 33% of 
radius and total radius) using a Lunar Prodigy densitometer, 12165 (GE Medical 
Systems) . The precisions for duplicate measurements were 0,9% for lumbar spine, 
0,5% for left total hip and femoral neck and 2,8% for radius. All BMD results were 
expressed in absolute values (g/cm²) and as the number of standard deviations (SD) 
above or below the mean results of young female adults, T-score, and compared to an 
age matched female reference population consisting of approximately 12000 healthy 
women aged 20-80 in a pooled North European/ United States population 
167
, Z-score. 
Osteoporosis was defined according to World Health Organisation (WHO) as a BMD 
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value at or below -2,5 SD, and osteopenia between -1 and -2,5 SD, compared to the 
young adult mean value measured at any site using DXA 
52
.  
Vertebral fractures 
Paper II-IV. Each patient had two lateral conventional radiographs, one of thoracic 
spine and one of lumbar spine, taken. The vertebras were visually graded by Genant´s 
method 
107
 as normal (grade 0), mildly deformed (grade 1, approximately 20-25% 
reduction in anterior, middle and/or posterior height and a 10-20% reduction in area), 
moderately deformed (grade 2, approximately 25-40% reduction of any vertebral 
height and a reduction in area of 20-40%), and severely deformed (grade 3, 
approximately 40% reduction in any vertebral height and area). A vertebrae graded 1, 
2 or 3 was regarded as fractured. One radiologist (S.H) evaluated all radiographs. 
Statistical analysis 
In paper I Pearson´s Correlation was used in simple regression analyses with BMD or 
cumulative corticosteroid dose as dependent variables and demographic and disease-
related variables as independent variables. In paper II-IV all variables were tested with 
Kolmogorov-Smirnov ´s normality test. Pearson´s Correlation was used when 
variables were normally distributed otherwise Spearman´s rank Correlation was used. 
Unpaired t-test was used to compare numeric data (paper I-IV). One example is when 
we compared BMD-values between pre- and post-menopausal women (paper I). 
Mann-Whitney U-test was used for comparisons of not normally distributed variables 
between patients with or without vertebral (paper II). Categorical data have been 
compared with χ²-test (paper I-IV).  
In paper I observed BMD-values were compared with each patient’s expected BMD-
value by sign test. Multiple regression analyses, forward stepwise method, have been 
performed to explore the relationship between BMD in different sites and 
demographic and disease-related variables (paper I). The same method was used with 
PCS as dependent variable in paper III and with resistin as dependent variable in paper 
IV. Independent variables were demographic and disease-related variables that had 
shown significant correlations in simple regression. Logistic regression, forward 
conditional method, was used to explore relationships between a categorical dependent 
variable and covariates (paper II-IV). The significance of the logistic regression 
analyses was expressed by calculating an area under ROC curve with confidence 
interval (paper II-IV). In paper IV correlations between serum resistin levels and ages 
in SLE-patients and controls are compared. The constant and the regression 
coefficient, with respect to resistin values and age, were compared to the 
corresponding parameters of the controls by use of a special t-test. All tests were two-
tailed and p<0,05 was considered statistically significant. 
 37 
Main conclusions from the thesis 
Paper I 
BMD in female SLE patients was compared to reference values of BMD. The 
reference BMD for each patient was calculated from equations derived from the DXA 
adjusting it for age and weight. Risk factors associated to low BMD were calculated. 
We found that the SLE patients had significantly lower BMD than the healthy 
references in all measured sites. Patients fulfilling our present criteria for treatment 
against low BMD, either osteoporosis or osteopenia and glucocorticosteroid 
medication, were seldom treated adequately. Risk factors of low BMD were known 
factors like high age and low weight but also markers of inflammation, impaired renal 
function and disease damage. These results show the need of better awareness of 
osteoporosis and adequate treatment of low BMD. Since systemic inflammation in 
SLE is associated to low BMD we hypothesis that glucocorticosteroid medication by 
suppression of the systemic SLE inflammation in some circumstances, could preserve 
BMD.  
Paper II 
Low BMD is one of several known risk factors of fragility fractures. In this study we 
analysed the prevalence of vertebral fractures in SLE. We also wanted to establish 
possible SLE-specific factors associated to vertebral fractures in our patient cohort. 
The results show that vertebral fractures are frequent but they are seldom clinically 
diagnosed. Although 52% of the patients were on medication with 
glucocorticosteroids, there was no association between treatment with 
glucocorticosteroids and vertebral fracture in this study. We found no independent 
correlation between SLE-specific factors and vertebral fractures. High age was the 
most important factor associated with vertebral fracture. A high percentage (40%) of 
patients with vertebral fractures had normal BMD in all measured sites indicating the 
importance of other biomechanical properties then BMD for bone strength. Until 
disease specific factors affecting bone strength are found, established risk factors of 
osteoporosis and fractures in general population must be used to guide the clinician to 
select SLE patients for x-ray.  
Paper III  
Health quality is a subjective experience not necessarily dependent on having a 
disease. In this study we analysed self-reported physical and mental HRQOL and its 
relationship to disease variables, vertebral fractures and employment status. The SLE 
patients scored significantly lower HRQOL in all measured health domains compared 
to age and sex matched controls. We found associations between physical component 
summary score (PCS) and BMI, disease activity, glucocorticosteroid dose, age and 
SLICC. When patients 20-64 years old were analysed, working capacity was highly 
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significantly associated with PCS. Patients working full or part time rated all measured 
health domains, both physical and mental, higher than patients not working. There was 
no difference in disease activity, DMARD treatment or prevalence of vertebral 
fractures between the groups although patients working were younger and had shorter 
disease duration and lower SLICC. When aiming at better HRQOL in SLE, factors of 
importance to working ability should be given special attention. 
Paper IV 
Resistin is a recently described secretory peptide with proinflammatory properties in 
humans. We investigated relations between resistin and other markers of 
inflammation, kidney function and BMD in SLE. Serum levels of resistin 
measurements did not differ between patients and healthy controls, possibly reflecting 
that we measure the spill-over from local tissue compartments in the circulation.  In 
spite of this, resistin was associated to inflammation, renal function, 
glucocorticosteroid treatment and BMD.  Resistin is a marker of inflammation but we 
do not know if it has pathophysiological significance in SLE. We suggest that resistin 
can be a linkage between inflammation and deteriorating bone quality in SLE. Further 
studies are encouraged. 
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Popularized summery in Swedish (Populärvetenskaplig 
sammanfattning) 
Systemisk Lupus Erythematosus (SLE) är en autoimmun sjukdom som till 
övervägande del drabbar kvinnor. Av patienterna är 9 av 10 kvinnor och de flesta 
insjuknar i fertil ålder. Sjukdomen är vanligare i svart och asiatisk befolkning än bland 
kaukasier. I Sverige har ungefär 68 av 100 000 invånare SLE medan det årligen 
nyinsjuknar 4-5 personer per 100 000 invånare. 
Sjukdomen är multifaktoriell vilket vid SLE betyder att såväl genetiska som 
hormonella och miljöfaktorer är betydelsefulla för utveckling av sjukdomen. De gener 
som är av betydelse hör samman med immunsystemet. Solljus är en miljöfaktor som 
har visats kunna försämra sjukdomen liksom det kvinnliga könshormonet östrogen. 
De flesta SLE patienter har autoantikroppar mot beståndsdelar i cellkärnan (ANA) och 
mot arvsmassan (anti-DNA). Det kan också finnas andra autoantikroppar. Många har 
inflammation i huden med hudutslag, smärta och svullnad i leder eller sår i 
munslemhinnan.  Det kan förekomma utgjutning i lungsäck och hjärtsäck samt 
inflammation i njurar och centrala nervsystemet. Inflammationen vid SLE behandlas 
med immun- och inflammationsdämpande mediciner bl.a. kortison och ibland 
cellgifter. 
Benskörhet eller osteoporos är ett tillstånd i skelettet när benmineraltätheten (BMD) är 
nedsatt. Vid osteoporos är skelettets hållfasthet sänkt och det är lättare att ådra sig 
benbrott. Ett vanligt brott på skelettet vid osteoporos är kotfrakturen där kotan pressas 
samman. 
Vi har undersökt BMD hos 163 kvinnor med SLE. Undersökningsmetoden är dual 
energy x-ray absorptiometri (DXA), en form av lågenergiröntgen. Med utgångspunkt 
från ett referensmaterial omfattande BMD på ca 12 000 personer kunde vi räkna fram 
hur varje patients BMD ”borde” vara med hänsyn tagen till ålder och vikt. SLE-
patienterna hade genomsnittligt lägre BMD än var de borde ha haft. De faktorer som 
var associerade till låg BMD var tidigare kända allmänna riskfaktorer som hög ålder 
och låg vikt men även inflammation, sänkt njurfunktion och sjukdomsskada av SLE-
sjukdomen var betydelsefulla. Vi fann först ett samband mellan kortisonmedicinering 
och BMD men det sambandet kvarstod inte när fler faktorer togs med i analysen. 
Regelbunden fysisk aktivitet var skyddande för skelettet i höfterna. Få patienter med 
indikation för behandling av osteoporos hade denna medicinering.  
Samtliga 163 patienter röntgade också ryggen för bedömning av om det förelåg 
frakturer i form av sammanpressade kotor, kotkompressioner. I denna del av studien 
kunde 150 patienter bedömas då 12 röntgenbilder vattenskadats under lagring och en 
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bild förkommit. Fyrtiotre (29%) av patienterna hade tillsammans 95 kotkompressioner 
men bara 6 (4%) hade tidigare fått sin kotfraktur diagnostiserad. Det betyder att så 
många som 25% av hela patientantalet hade minst en kotfraktur utan att veta om det. 
De flesta frakturerna satt i mellersta bröstryggen. Andelen patienter med kotfraktur 
steg med ökande ålder. Flera faktorer var associerade med kotfraktur men hög ålder 
var den viktigaste riskfaktorn. Man vet sedan tidigare att kortisonbehandling leder till 
ökad risk för låg BMD och frakturer. I denna studie har vi inte funnit dessa samband. 
Det kan bero på studiens utformning, men det kan också bero på att inflammationen 
vid SLE i sig är skadlig för skelettet. Kortison i låga doser skulle då kunna minska 
inflammationen så att nettoeffekten blir positiv för skelettet, BMD bibehålls.  
Hälsa är definierat av Världshälsoorganisationen (WHO) som "ett tillstånd av 
fullständigt fysiskt, psykiskt och socialt välbefinnande, och inte enbart frånvaro av 
sjukdom eller handikapp”. Olika aspekter på hälsorelaterad livskvalitet (HRQOL) kan 
mätas med frågeformulär. Vi har använt den svenska versionen av SF-36 som med 36 
frågor mäter 4 psykiska och 4 fysiska hälsoområden. Vi frågade också alla patienter 
om de yrkesarbetade/studerade, var arbetssökande, sjukskrivna, ålders eller 
sjukpensionärer. I samtliga hälsoområden skattade SLE patienterna sin hälsa som 
sämre än vad ålders och könsmatchade referenspersoner gjorde. Bland personer 64 år 
och yngre var låg fysisk hälsa associerad till låg arbetsförmåga, hög SLE aktivitet, hög 
kortisondos och högt BMI. Inga av de faktorer som vi analyserade var associerade till 
mental hälsa. Det som kännetecknade en yrkesarbetande patient var yngre ålder och att 
man uppfattade liten påverkan på två av områdena inom fysisk hälsa (fysisk funktion 
och rollbegränsning av fysiska orsaker). Denna del av studien visar att HRQOL 
påverkas av många faktorer förknippade med SLE. Den visar också på en möjlighet att 
förbättra HRQOL genom förbättrad SLE-behandling såväl som genom påverkan av 
faktorer förknippade med arbetsoförmåga. 
Resistin är ett ämne, en cytokin, som finns i förhöjda nivåer vid flera inflammatoriska 
sjukdomar och tillstånd. Det är tidigare inte är undersökt om det är så även vid SLE 
eller om resistin kan associeras till inflammation vid SLE. Nivåerna av resistin i serum 
skilde sig inte mellan SLE patienterna och de friska kontrollerna. Trots det var resistin 
associerat till inflammation, sänkt njurfunktion, högre pågående kortisondos, sänkt 
BMD och lågt high-density lipoprotein (HDL, ”det goda kolesterolet”). Inflammation, 
sänkningsreaktion, var den faktorn som resistin var oberoende associerat till. Vi tror att 
resistin kan vara ett ämne som hjälper till att driva inflammationen i SLE och inte bara 
är en markör för inflammation. Resistin kan också vara betydelsefullt i samspelet 
mellan benomsättning och inflammation. Det skulle då kunna vara en angreppspunkt 
för framtida behandlingar.  För att säkert kunna veta hur det ligger till behövs fler 
studier om hur reistinnivåer förändras med patienternas sjukdomsaktivitet. Dessutom 
behövs studier som belyser hur resistin utövar sin effekt i kroppen. 
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